Unusual Cutaneous Location of Langerhansian Histiocytosis: A Case Report

Review began 11/01/2021

Review ended 11/13/2021

Published 11/16/2021

© Copyright 2021

Bendari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Mounia Bendari¹, Idriss Chamizakhraji², Saloua Elamari³, Kenza Oqbani⁴, Maryame Ahnach²

1. Hematology Department, Cheikh Khalifa International University Hospital, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR 2. Hematology Department, Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR 3. Endocrinology Department, Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR 4. Pathology Department, Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, MAR

Corresponding author: Mounia Bendari, mbendari@um6ss.ma

Abstract

Langerhansian cell histiocytosis (LCH) is a rare pathology characterized by the proliferation of CD1+ and langerin+ cells. It can affect all ages, with an estimated prevalence of one to two cases/100,000 inhabitants. The involvement is often multi-visceral; however, isolated cutaneous involvement can be found in 40% of cases with very variable manifestations. We report the case of 45-year-old women followed for non-insulin-dependent diabetes and primary hyperparathyroidism suffering from isolated and refractory cutaneous histiocytosis.

Categories: Dermatology, Endocrinology/Diabetes/Metabolism, Hematology

Keywords: relapse, chemotherapy, skin involvement, langerhans cells histiocytosis, adult

Introduction

Paul Langerhans was the first to describe the Langerhans cell in 1868 [1]. Alfred Hand reported the first definitive case of Langerhans cell histiocytosis (LCH) in 1893 [2]. It mainly affects children under three years of age (4 to 5 per million children 0 to 15 years of age each year) and the incidence in adults is around 1-2/million; it appears that the incidence is higher in Caucasians in northern European countries and lower in Asia and Africa [3-4]. LCH is characterized by variable clinical presentation and heterogeneous prognosis with common histopathological aspects; it's characterized by an infiltration of the body's tissues by atypical Langerhans cell histiocytes, often organized in granulomas. Langerhans cells or histiocytes are immature dendritic cells that are found mainly in the skin and the multilayered mucous membranes of the body [5-6]. Clinical presentations are very diverse, ranging from a single lesion to severe multi-visceral forms. We report the case of 45-year-old women followed for non-insulin-dependent diabetes and primary hyperparathyroidism with refractory and multifocal cutaneous histiocytosis. Through our case, we illustrate the particularity of cutaneous presentations of histiocytosis and underline the real challenge in the diagnosis and management of this rare entity. The major aim of our report is to describe the characteristics of the cutaneous form of this disease, especially when they are refractory.

Case Presentation

We report a case of a 45-year-old woman, a non-smoker, treated for type II diabetes under insulin and primary hyperparathyroidism. Her medical history dates back to 2006 with an infiltrated nodule associated with ulcers that grew gradually in her right thigh. The patient underwent surgery with an anatomopathological study. Skin biopsy objectified ulcerated epidermotropic dermo-hypodermal tumor proliferation whose morphological appearance and immunohistochemical data are in favor of LCH. Langerhans cells present positivity of the anti-PS100 antibody, anti-CD1a antibody, and anti-Ki67 antibody (60%), and negativity of the anti-CD68 antibody. The patient subsequently received 25 sessions of radiotherapy followed by six courses of chemotherapy with a low dose of oral methotrexate. After these treatments, skin lesions are stable. In 2020, the patient complained of an increase in skin lesions, with the appearance of several infiltrating nodules, scaling, crusted papules, and ulcerated plaques. The patient received chemotherapy as single-system LCH (SS-LCH) based on methotrexate, associated with prednisone and vinblastine, with the obtainment of stable response and limited regression of the lesions. After two courses, the patient was lost to follow-up. One year later, the oncologist referred the patient to the hematology department for a major increase in skin lesions, with the appearance of new ones on her thigh. Dermatological examination found ulcers and necrotic lesions, purplish, well-limited, of variable size, not painful, not warm to the skin, and localized to the right thigh. The mucous membranes and integuments were unharmed (Figure 1).

How to cite this article

Bendari M, Chamizakhraji I, Elamari S, et al. (November 16, 2021) Unusual Cutaneous Location of Langerhansian Histiocytosis: A Case Report. Cureus 13(11): e19617. DOI 10.7759/cureus.19617

FIGURE 1: Skin lesion of LCH

Ulcers and necrotic lesions, purplish, well-limited, of variable size, not painful, not warm to the skin, and localized to the right thigh

LCH: Langerhansian cell histiocytosis

Furthermore, the examination found an afebrile, obese patient (body mass index (BMI) at 44.8). Abdominal and cardiovascular examinations were unremarkable. The physical examination did not find any tumoral syndromes, and the patient did not present have B signs (fever, weight loss, and night sweats). A complete assessment was carried out in favor of a cutaneous location without visceral involvement. A CT scan of the chest and abdomen was normal. Extensive investigation revealed no systemic involvement, central nervous system (CNS) evaluation was not done, serum thyroid hormone levels were normal, endocrine workup was performed, including cortisolemia, and parathormone assessment were done in favor of primary hyperparathyroidism. A skin biopsy was performed. The microscopic examination revealed a cutaneous tissue with an infiltrate of large cells involving the dermis and realizing an epidermotropism. The infiltrate was composed of atypical cells with abundant, pale eosinophilic cytoplasm, irregular and elongated or lobed nuclei with prominent nuclear grooves and folds, fine chromatin, and indistinct nucleoli. Multinucleated giant tumor cells, high cytonuclear atypia, and marked nuclear pleomorphism were seen. The mitotic figures were increased. The neoplastic cells also showed a mixed inflammatory background with variable numbers of reactive lymphocytes, plasma cells, benign histiocytes, and eosinophils associated (Figure 2).

FIGURE 2: Langerhans cell (LC) sarcoma, microscopic exam

A: large cells dermal infiltrate (low power field H&E); B: irregular and elongated nuclei with prominent nuclear grooves and folds (high power H&E); C: nuclear pleomorphism and variable inflammatory infiltrate surrounding neoplastic tumor cells (high power H&E)

The immunohistochemical stains had shown a diffuse strong and heterogeneous positivity for CD1a and S100 and variable positivity for CD45. All other markers studied were negative, including CD68, cytokeratins (AE1/AE3), and melanocytic marker (MelanA). The Ki-67 proliferation index was high (50%) (Figure 3).

FIGURE 3: Langerhans cell (LC) sarcoma, immunohistochemistry

A: S100 was widely represented, nuclear and cytoplasmic, but variable in intensity.

B: Neoplastic cells expressed surface CD1a.

C: Ki-67 stain showed a high proliferation rate.

D: Tumor cells were negative for cytokeratins (Note the epithelial cells positive control).

In the light of microscopic and phenotypic results, the diagnosis of Langerhans cell sarcoma was confirmed. The patient did not receive any maintenance therapy and she received only two courses of chemotherapy; consequently, the patient was included in the LCH protocol as single-system LCH (SS-LCH), and she received the same chemotherapy combining prednisone ($60 \text{ mg} / \text{m}^2$), high-dose of methotrexate ($5000 \text{ mg}/\text{m}^2$), and vinblastine ($10 \text{ mg}/\text{m}^2$). The evolution was favorable after five cycles of chemotherapy with significant regression of lesions in the thigh without the appearance of any new lesions (Figure 4).

FIGURE 4: Skin lesions after three courses of chemotherapy

Favorable response after chemotherapy

Discussion

Langerhansian cell histiocytosis (LCH) is a pathology characterized by the proliferation of Langerhans cells in various organs, such as bone, liver, spleen, or even the skin. Involvement of the skin is found in 40% of cases; it mainly affects children [5,7]. In the 2016 revised classification of the Histiocyte Society, LCH is currently defined as an inflammatory myeloid tumor [8]. Among the most affected organs, the bone is the most touched (80%), the skin is also affected (40%), and the pituitary (25%), liver, spleen, lungs, and central nervous system can also be touched [9]. In general, the involvement is multisystem or multifocal, rarely isolated to a single organ. Bone and lungs are the two organs most affected in the localized form, unlike cutaneous histiocytosis, which is rarely isolated in adults and is mainly present in multisystem forms of the disease. In fact, the involvement is multisystem or multifocal, rarely isolated to a single organ. As mentioned in the observation of this patient, we report the case of isolated skin involvement; skin involvement manifested as ulcerative necrotic lesions of varying sizes. Likewise, during histiocytosis, it is usual to find diabetes insipidus due to pituitary involvement [1]. For our patient, she had type II diabetes with primary hyperparathyroidism. The cutaneous presentations can be very variable, lesions can be papular or papulovesicular, nodular, hemorrhagic, seborrheic, scaly, or ulcerated lesions. The scalp, folds of the body, external genitals, and hairless skin are the main sites of cutaneous damage [6]. Our patient had heterogeneous skin lesions but all localized to her thigh. The diagnosis of histiocytosis is based on the histological examination of the affected organ, which shows a granuloma with Langerhans cells, the appearance of which varies depending on the stage of development and the tissue involved. The Langerhansian nature can be confirmed in immunohistochemistry by the expression of the membrane antigen CD1a or Langerin (CD207). The diagnosis of LCH is not easy; for our patient, many skin biopsies with immunohistochemistry studies were performed to confirm the diagnosis.

Significant advances have been made in understanding the pathogenesis of LCH since 2010 due to the discovery of the presence of the gain-of-function mutation in BRAF (V600E) in more than half of the samples from patients with LCH [10-11]. Since then, several studies have reported that 100% of LCH cases present with ERK phosphorus, suggesting that LCH is probably a clonally expanding myeloid neoplasm [12]. Moreover, the presence of the BRAFV600E mutation has been reported in tissue samples of half of the patients, and it has been shown that the activation of the RAS-RAF-MEK-ERK pathway is always present in LCH lesions, regardless of BRAF status. These results represent an important step in understanding the pathophysiology of the disease [13]. Regarding treatment, patients with single-systemic disease confined to a single site generally required only local treatment. Systemic treatment is possible in some cases for localized form [7]. In more extensive forms, systemic treatment is usually necessary [14-15]. In fact, the treatment of skin involvement is based on the excision of the lesion with topical corticosteroids if it is limited. For refractory forms, more complex protocols can be proposed (mono or poly-chemotherapy). The response of treatment is usually favorable for adults [6] and for isolated localization. However, our patient presented several relapses, leading to the use of several lines of therapy. Unfortunately, our patient was not tested for BRAF status. The treatment of LCH remains controversial. Indeed, therapeutic management depends on the number of sites affected, the severity of the lesions, and the age of the patient. Many

therapies have been tried such as chemotherapy, radiotherapy, or surgery [16]. For our patient, after relapse, the LCH protocol (vinblastine and high-dose methotrexate (MTX)) was chosen, and permits having a favorable response. The aim of this report is to highlight the difficulties of diagnosis and management of this particular disease. Our patient is an adult woman, with only skin localization, which is rare for histiocytosis. Also, localization at the level of the thigh is not common for LCH.

Conclusions

LCH is a rare pathology that has multiple clinical presentations. The diagnosis must be made with precision, and the extension assessment allows patients to be classified and treated according to whether the involvement is multifocal or limited to a single organ. The outcome is often favorable with treatment, but relapses can occur even in localized cases. Recent publications report the interest of the research on the BRAF (V600E) mutation to confirm the diagnosis of LCH.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Langerhans P: Ueber die Nerven der menschlichen. Haut. Arch Abl B Pathol. 1868, 44:325-37.
2. Hand AR: Polyuria and tuberculosis. Arch Pediatr. 1893, 10:673-5.
3. Carstensen H, Ornvold K: The epidemiology of LCH in children in Denmark. Med Pediatr Oncol. 1993, 21:387-8.
4. Swerdlow SH, Campo E, Harris NL, et al.: WHO classification of tumours of haematopoietic and lymphoid tissues. In: Weiss LM, Jaffe R, Facchetti F, eds. of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, 4th Edn. Weiss LM, Jaffe R, Facchetti F (ed): IARC, Lyon; 2017. 2:
5. Sun WG, Zhong LS, Chen H: A case of adult generalized cutaneous Langerhans cell histiocytosis. Ann Dermatol. 2016, 28:262-4. [10.5021/ad.2016.28.2.262](#)
6. Wang X, Yang S, Tu P, Li R: A case of Langerhans cell histiocytosis in an adult with initial symptoms confined to the skin. Int J Dermatol. 2010, 49:337-9. [10.1111/j.1365-4632.2009.04186.x](#)
7. Conias S, Strutton G, Stephenson G: Adult cutaneous Langerhans cell histiocytosis. Australas J Dermatol. 1998, 39:106-8. [10.1111/j.1440-0960.1998.tb01259.x](#)
8. Emile JF, Abia O, Fraitag S, et al.: Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016, 127:2672-81. [10.1182/blood-2016-01-690636](#)
9. Meyer JS, Harty MP, Mahboubi S, et al.: Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation. Radiographics. 1995, 15:1135-46. [10.1148/radiographics.15.5.7501855](#)
10. Kobayashi M, Tojo A: Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci. 2018, 109:3707-13. [10.1111/cas.13817](#)
11. Badalian-Very G, Vergilio JA, Degar BA, et al.: Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010, 116:1919-23. [10.1182/blood-2010-04-279083](#)
12. Haroche J, Charlotte F, Arnaud L, et al.: High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012, 120:2700-3. [10.1182/blood-2012-05-430140](#)
13. de Menthon M, Meignin V, Mahr A, Tazi A: Adult Langerhans cell histiocytosis [Article in French]. Presse Med. 2017, 46:55-69. [10.1016/j.lpm.2016.09.015](#)
14. Monsereenusorn C, Rodriguez-Galindo C: Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015, 29:853-73. [10.1016/j.hoc.2015.06.005](#)
15. Bui AN, Puleo AE, Canales AL, Jacobsen ED, LeBoeuf NR: Cutaneous Langerhans cell histiocytosis responsive to topical nitrogen mustard. J Drugs Dermatol. 2020, 19:803-5. [10.36849/JDD.2020.4943](#)
16. Furudate S, Fujimura T, Kambayashi Y, et al.: Successful treatment of adult onset Langerhans cell histiocytosis with bi-weekly administration of pegylated interferon- α . Acta Derm Venereol. 2014, 94:611-2. [10.2340/00015555-1807](#)